Study
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001005180 | Other |
Study Description
We evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against Janus kinases. Solving the structure of FDA-approved type I JAK inhibitors ruxolitinib and baricitinib bound to the JAK2 JH1 tyrosine kinase domain enabled the rational design and optimization of Cereblon (CRBN)-directed JAK PROTACs utilizing multiple derivatives of JAK inhibitors, linkers and CRBN-specific molecular glues. The resulting JAK PROTACs were evaluated for target degradation by proteomic approaches, and activity tested in CRLF2-rearranged cell line and xenograft models of ALL.
Study Datasets 2 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001007569 |
RNAseq data set, Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
|
Illumina NovaSeq 6000 | 11 |
| EGAD00001007570 |
WGS data set of 11 xenograft samples, Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
|
Illumina NovaSeq 6000 | 11 |
Who archives the data?
Publications
Citations
Retrieving...
Retrieving...
